Return to search
A study of the effect of cotreatment of taprostene (CG 4203), a novel stabilized prostacyclin analogue, with saruplase, a gene technologically produced unglycosylated single chain urokinase-type plasminogen activator (r-scuPA), in thrombolysis in vivo
No description available.
Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:278267 |
Date | January 1990 |
Creators | Groves, Robert W. |
Publisher | University of Bath |
Source Sets | Ethos UK |
Detected Language | English |
Type | Electronic Thesis or Dissertation |
Page generated in 0.0013 seconds